FDA Advisory Panel Recommends Approval For TB Alliance’s Experimental Treatment For Drug-Resistant TB

Reuters: FDA advisory panel recommends approval of TB Alliance’s tuberculosis treatment
“Independent experts of an FDA advisory panel voted in favor of the not-for-profit TB Alliance’s treatment for drug-resistant tuberculosis, as a part of a three-drug combination regimen. The panel on Tuesday voted 14-4 when asked to assess the treatment, pretomanid, in combination with Johnson & Johnson’s bedaquiline and linezolid for multi-drug resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). Although the U.S. health regulator is not bound to follow the advice of its advisory panels, it usually does so…” (Maddipatla/Mathias, 6/6).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.